Las Vegas, NV -- (SBWIRE) -- 09/25/2013 -- Value Stock Pick is a leading Investment Newsletter. Our Research Team conducts research on different stocks, doing their due diligence to provide a detailed report, including both technical and fundamental analysis, on NYSE, NASDAQ, AMEX, OTCBB and Pink Sheet Stocks. Let’s have a brief look at: Omeros Corporation(NASDAQ:OMER), Opexa Therapeutics Inc(NASDAQ:OPXA), BioTelemetry Inc(NASDAQ:BEAT), Aastrom Biosciences Inc(NASDAQ:ASTM)
Omeros Corporation(NASDAQ:OMER) endedlower -1.31% and complete the day at $9.06. The total number of shares changed hands during the day was 2.40 million. After opening at $9.17, the stock hit as high as $9.65. However, it traded between $3.65 and $11.85 over the last twelve months. Omeros Corporation, a clinical-stage biopharmaceutical company, engages in discovering, developing, and commercializing products targeting inflammation, coagulopathies, and disorders of the central nervous system.
Has OMER Found The Bottom and Ready To Move Up? Find Out Here
Opexa Therapeutics Inc(NASDAQ:OPXA) closed yesterday at $1.91, a +6.11% increase. Around 2.40 million shares were traded, beating an-average trading volume of 1.17 million shares. The company is now valued at around $38.42 million. Opexa Therapeutics, Inc., a biopharmaceutical company, develops personalized cellular therapies to treat multiple sclerosis (MS) based on its proprietary T-cell technology.
For How Long OPXA’s Gloss will Attract Investors? Find out via this report
BioTelemetry Inc(NASDAQ:BEAT) moved +14.05 percent higher at $10.47 and traded between $9.27 and $10.63 opening the day at $9.29. Its performance over the last five days remained +38.49%, which stands at +38.49% for a month. Going back further than one month, 1-year performance after recent close was +359.21%. BioTelemetry, Inc. provides cardiac monitoring, cardiac monitoring device manufacturing, and cardiac core laboratory services.
Will BEAT Continue To Move Higher? Find Out Here
Aastrom Biosciences Inc(NASDAQ:ASTM)’s shares drop, losing -0.96 percent to close at $0.278. The stock is up around -77.9% this year and -84.09% for the last 12 months. Around 2.39 million shares changed hands yesterday, higher from an-average trading volume of 1.97 million shares. Aastrom Biosciences, Inc., a development stage company, engages in the development of patient-specific, cell products for use in the treatment of severe, chronic ischemic cardiovascular diseases.
Will ASTM Get Buyers Even After The Recent Rally? Find Out Here
Value Stock Pick is a leading Investment Newsletter. Our Research Team conducts research on different stocks, doing their due diligence to provide a detailed report, including both technical and fundamental analysis, on NYSE, NASDAQ, AMEX, OTCBB and Pink Sheet Stocks.
PLEASE NOTE WELL: The employees of ValueStockPick.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site, Press releases or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Please Read Our Full Disclaimer at http://www.valuestockpick.com/disclaimer/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)